Pps went down, but your stock buy gives our sagging confidence a boost. Please encourage the other highly paid LPath officers to follow your lead to show us a clear and bright sign that all is well with our Mabs and that we are all in this little boat together.
Just talking about the need for some confidence-boosting insider buys, then the following week Scott buys. Maybe an honest attempt by Scott to boost pps, but I guess buying 10,000 shares was not much of a confidence boost. Instead, it made many investors doubt as to how good the trial results are going with the CEO not willing to put 100,000$ on the table. INO CEO bought more than $2M worth of 250,000 shares. Now, that is really saying that their technology will definitely work, even though it may not in the end. Scott only owns 106k shares with the last filing and brought attention to the 6000 shares he sold in Feb. Let's see if other insiders will show more conviction in LPath.
Today will be my last buy. Don't want to risk anything anymore. This is just badly played and manipulated. Lpath should just go private until Isonep results are out.
But his asking price was 3.05, and that is what brought the pps down. I outbid him since I got mine at 3.15. To further outdo him, I'm thinking of adding more at 3.20.
Is there any way to stop trading for 6 months?
Why is Russia punishing it's own people? Putin's gonna starve the Russians like Stalin did. Will Snowden still be a happy Russian?
Are you not feeling insecure now that it seems you're not the only knowledgeable pumper on this board? LOL!
Anyway, welcome to the other well-informed posters.
I'm buying if that insider selling pulls this back down below 9. I actually added too soon at 9.30.
I was thinking that he might be dying and needs to put his finances in order. If he is staying, he probably has more than 100,000 unvested options still remaining.
We have a ghost ship; it doesn't really sink. Right now, we are underwater, but we expect it will surface sometime like it's supposed to.
If we get desperate, we might need to toss Charles overboard to get it afloat.
Junius is expecting new licenses. New partners will be bigger news. But ASH in Dec might bring news on the SAR products and BT062. There's also AACR in October. Many things can happen that might bring it to 13 by Jan. If Ukraine is settled by then, pps could even be higher.
INO went up more than 10% bec of the CEO buy.
Go, Scott, go! Fire those missiles before the Islamic State shorts do more damage to the pps.
but not LPath CEO, unfortunately. Not yet anyway. INO CEO purchase a total of more than $2M at price of $9 pps.
That's the way to do it, Scott. Rally the boys! Go, ,Scott, go!
Hey, I only have one non-biotech in my portfolio - VHC. It may be quite a gamble, although recent events favor the upside. You may want to look at it.
I don't know what the upside to ARNA is considering the low sales and a pipeline that has probably less substance than Immunogen's. I made a mistake of leaving EXAS back at $5 (and TROV) because genes can't be patented for diagnostic purposes.
I don't know where IMGN's stock price is gonna go, so I go more with calls at this time so that I will have less money tied up. 2015 might really be a better time for a longer investment or before ASH 2014.
IMGN isn't testing safety on healthy subjects for ph1. Instead, IMGN went with subjects with relapsed NHL making recruitment difficult. They are probably hoping to see good activity in that patient group and advance the drug to phase 2/3 based on that.
How come your other stock picks are making you money, but not LPTN? When am I gonna make money on this one?
Anyway, good job on MNKD. Do you think you're actually going to prefer their inhaler over other options?
I criticize the ruling...but also these outrageous drug prices despite being a biotech investor.
Folate alpha receptor peptides are loaded on to the patients’ own dendritic cells for ovarian cancer. FRs are expressed 100x more in OC cells than in normal cells.